Abstract A total of 679 families who had at least one child with fragile X syndrome (FXS) were recruited from a research registry to participate in a survey examining cascade testing and communication about FXS. Families had a total of 1117 children (804 males, 313 females). Most families (84 %) had tested all of their children. The main reason for not testing, which did not differ by gender or age of the child, was that the child did not show signs of FXS (68 %). Families talked with their children about FXS occasionally (47 %) although 16 % said they do not talk about it. Most families (66 %) had told their children their FXS status, with males and those with the premutation being less likely to be told test results. Of those that did not, 46 % said that they would tell their child when they were old enough to understand, whereas 34 % had either decided they would not tell or were not sure if or when they were going to tell. About a quarter of respondents (28 %) indicated that no extended family members had been tested, with income and communication about FXS being the strongest predictors. Results from this large scale survey provide important data on how families communicate about FXS and reasons testing is or is not sought. This information can be used by genetic counsellors in providing follow-up to families after a FXS diagnosis.
Introduction
Fragile X syndrome (FXS) is the most common inherited single-gene cause of intellectual disability. FXS results from an expansion of a trinucleotide repeat (CGG) on the 5′ untranslated region of the FMR1 gene. Individuals with 55-200 repeats have the premutation. Higher numbers of CGG repeats are likely to become unstable in future generations and may lead to the full mutation of FXS (Fu et al. 1991) . Affected individuals are those who have more than 200 repeats. Females with the premutation have a 50 % chance in each pregnancy of passing on their affected gene to their offspring. Females with the premutation are most likely to pass on the full mutation of FXS if they have 90 repeats or more (Heitz et al. 1992) . Males with the premutation can only pass along the premutation to their daughters; there is no risk of expansion to the full mutation in one generation. Due to the inheritance pattern of FXS, multiple family members, both within a proband's family and those in their extended family, can be at-risk.
In the full mutation, methylation occurs during gestation, silencing FMR1 transcription (Jin and Warren 2000) . This leads to a reduction or absence of fragile X mental retardation protein (FMRP), which is needed for normal brain development. Males with FXS have moderate intellectual disability, attention problems, hyperactivity, autism, and behavior problems (Bailey et al. 2008a; Boyle and Kaufmann 2010) . Females are often less severely affected due to the existence of a second non-affected X chromosome, although there is wide variability in expression Keysor and Mazzocco 2002) . Premutation carriers are at risk for two associated conditions -fragile X-associated primary ovarian insufficiency (FXPOI) and fragile X-associated tremor ataxia syndrome (FXTAS) -as well as other physical and emotional consequences (Bailey et al. 2008b; Bourgeois et al. 2009; Hagerman and Hagerman 2004; Leehey et al. 2008; Sherman 2000) .
Although there is ample evidence about the genetics and inheritance of FXS, not much is known about what happens within families after a child is diagnosed. Specifically, we sought to better understand how families communicate about FXS both with their children and their relatives and determine what factors played a role in testing other children as well as extended family.
Diagnosis of FXS
Several professional and advocacy organizations have developed guidelines for testing children for FXS. The American Academy of Pediatrics (AAP) recommends that all children who are diagnosed with general developmental delay or intellectual disability be screened for FXS as a first-line test (Moeschler et al. 2014) . Further guidance from AAP is available on genetic testing and counseling for FXS (Hersh and Saul 2011) . The American College of Medical Genetics (ACMG) has created guidelines for referral and diagnostic testing for FXS (Sherman et al. 2005) . A more recent review of different screening options to identify individuals with FXS and carriers, including individual and population-based screening, can be found in Abrams et al. (2012) . Practice guidelines for the National Society of Genetic Counselors provide additional information on counseling considerations, reproductive issues, as well as treatment and resources .
Despite these guidelines and recommendations, the average age of diagnosis of FXS is around 36 months (Bailey et al. 2009 ). FXS is diagnosed through polymerase chain reaction (PCR) and Southern blot analysis (Spector and Kronquist 2006) . Families typically find out about FXS through the testing of one of their children because they present with cognitive or behavioral delays, often after a diagnostic odyssey by parents (Bailey et al. 2009; Bailey et al. 2000; Bailey et al. 2003) . The early developmental profile of FXS is not well described although studies show developmental differences in the communication and cognitive domains in children as young as 9 months (Bailey et al. 1998; Roberts et al. 2001; Roberts et al. 2009 ).
Studies have suggested that delays could be detected in more severely affected males with FXS through developmental screening by 9-12 months (Mirrett et al. 2004; Wheeler 2011) .
Because of the lengthy diagnostic process and with the urging of many advocacy organizations, it has become increasingly common to offer population-based screening for FXS to women and newborns (Hill et al. 2010) . In a recent national survey, women who have a child with FXS were asked when would they have liked to have known they were a carrier, and the majority said pre-conception screening would have been preferred (Bailey et al. 2011) . Attitudes about population-based prenatal testing in general are very positive (Fanos et al. 2006) . Uptake rates for preconception screening range from approximately 8 % to 21 %, with rates of 80 % and higher internationally perhaps due to free testing (Hill et al. 2010; Metcalfe 2012) . Women who wanted testing indicated that learning about risk of having a child with FXS, learning about the risk of FXPOI, and assessing their reproductive options were all benefits of preconception testing (Archibald et al. 2009 (Archibald et al. , 2013 . Interviews with women who had been identified as carriers of FXS through a general population screening had an array of reactions to the diagnosis, ranging from indifference to significant implications for current relationships or future family planning (Anido et al. 2007) .
Newborn screening for FXS has been more controversial. Although newborn screening would be one way to know the true prevalence of FXS, there are a host of ethical, legal, and social implications that need to be considered (Bailey et al. 2008a; Bailey et al. 2005) . Data from a pilot study in North Carolina found that parents declined newborn screening for a variety of reasons including not wanting to know the results or worry about the implications of a diagnosis and negative opinions about genetic testing or the testing of children .
Sharing Testing Results with Children
A series of studies have investigated when is the preferred time to test at-risk children for FXS and share test results. In the first study, Wehbe et al. (2009) found that those who had been tested, both carriers and noncarriers, thought testing should be offered at younger ages than did those at risk for FXS but who had not been tested. Almost half (45 %) of the participants had been tested and told their carrier status by age 13. When asked to reflect on learning about their carrier status, only a few individuals said they wished they had learned earlier or had been given more information, but the majority indicated they would not change anything. Another study using the same sample found that those who knew their carrier status were more likely to be from families who used an open communication style than those who had not been tested ).
When parents were interviewed, the majority of those whose child had been tested reported having fairly frequent conversations about their carrier status; fewer had frequent conversations if their daughter was at-risk but had not been tested (McConkie-Rosell et al. 2011) . In general, when parents told daughters their test results, most reported that they understood the information. Many, however, noted that their daughters may not have a full understanding or appreciate the long-term consequences of their carrier status.
Communicating with Extended Family Members
Communicating genetic risk to extended family members is a complex process. Although it is generally seen as the responsibility of individual families to communicate risk information to relatives, many factors can influence when and how this is done (Bailey et al. 2014; Gaff et al., 2007) . Similar to communicating risk or carrier status to children, talking with relatives can take many different forms, from open and direct to passive or even circumventive and piecemeal (Forrest et al. 2003; McClaren et al., 2013) . Importantly, younger family members were seen as the most in need of this information (Forrest et al.) . A related factor was the relative risk for each family member (Forrest et al., McClaren et al.) . Familial-level factors, such as the nature of relationship with extended family members, preexisting communication patterns, and distance from identified family member (i.e., first-, second-or third-degree relative), also play a role in the communication of genetic risk (Gaff et al., 2007) .
One study specifically focused on communicating with extended family about the risk for FXS (Bailey et al. 2003) . Most reported that this experience was somewhat (34 %) or very (35 %) stressful. The most commonly reported challenge was that extended family did not want to know this information and decided not to seek testing. Some respondents also mentioned the difficulty of explaining FXS to family members and in particular the inheritance pattern. In a handful of cases, the news of genetic risk exacerbated already tenuous family relationships.
Cascade Testing
Once genetic risk is communicated to extended family members, studies have examined cascade testing, or the testing of additional family members once the proband has been identified, with results showing a wide range of uptake. For example, an early study conducted by van Rijn et al. (1997) found 26 % of at-risk relatives up to the fourth degree had been tested for FXS, with higher rates among first-degree relatives. More recently, a 17 % uptake rate of at-risk family members was found based on clinical audit (Forrest et al. 2012) . Another chart review study examining cascade testing from a base of 176 probands found that an additional 785 family members were identified with either the full mutation (29 %, 219 males and 8 females) or premutation (71 %, 59 males and 499 females) (Visootsak et al., 2014) . A case study examining cascade testing within a family after an infant had been identified as a carrier of FXS through a pilot newborn screening study found an additional 13 family members with the premutation out of 22 tested (Sorensen et al. 2013) .
Research Questions
The purpose of this study was to expand on earlier work conducted in family communication and cascade testing for FXS using a large national sample. Three research questions were addressed: 
Method Study Design
This study was part of a large national survey which investigated the needs of families who have at least one child with FXS or a permutation carrier. The survey covered a range of topics in various modules such as family adaptation to FXS, health care, social skills and adaptive behavior, functional skills, and the needs of adults with FXS. Families were recruited from a survey research registry, Our Fragile X World.
Respondents chose to complete a web-based survey (94 %) or a phone interview (6 %). The information gathered is all caregiver report, and genetic confirmation of FXS was not externally validated. The number of participants included in individual analyses varies slightly because of missing responses and skipped items.
Participants
A total of 679 families participated. The majority were Caucasian (92 %), with an additional 3 % identifying as Hispanic, 2 % as African American, and 3 % from other racial or ethnic backgrounds. One quarter of the families had incomes under $50,000, 19 % had an income of $50,001 to $75,000, 19 % from $75,001 to $100,000, and 37 % over $100,000. The majority of respondents were married (86 %), employed (63 %), and had at least a 4 year college degree (63 %). Most respondents were females (90 %).
Families had a total of 1117 children (804 males, 313 females): 773 with the full mutation (642 males and 131 females), 48 with the premutation (16 males and 32 females), 146 who had been tested but did not have FXS (73 males and 73 females), and 150 who had not been tested for FXS (73 males and 77 females). The average age of all children was 18.1 years (12.6 SD). Although many families had children who were grown adults, we use the term Bchild^throughout the remainder of the article despite their age.
Instrumentation
When enrolling in the survey research registry, respondents provided demographic information about the family (e.g., family income), as well as information about each child such as date of birth, gender, and genetic status. Families also reported on a variety of characteristics for each child, such as whether the child have ever been diagnosed of treated for several co-occurring conditions (attention, hyperactivity, aggression, self-injury, autism, seizures, anxiety, depression, developmental delay).
During the full survey, which was conducted in 2012, respondents were asked a variety of questions about cascade testing and family communication about FXS, including: family history of FXS before their first child was diagnosed; whether all their children had been tested and if not, why; how often they talked with their children and relatives about FXS; and how many relatives had been tested for FXS. Respondents were also asked to rate the impact that FXS had on their family. Survey items are available from the study author upon request.
Data Analysis
Both descriptive and regression analyses were conducted using the Statistical Analysis System (SAS, Version 9). First, percentages were calculated to provide descriptive data on categorical survey items. To account for missing data at the item level, percentages are based on the numbers of respondents who completed each question. Next, three logistic regressions were run to examine predictors of (1) whether a child had been tested for FXS, (2) whether the child had been informed of the test result, and (3) how many extended family members had been tested for FXS. The first two models were child-level analyses and used the same covariates: child gender, age, and total number of co-occurring conditions. The child tested model also included family income and family history of FXS as independent variables. The child told model included genetic status (premutation, full mutation, or no FXS) as a predictor. The final model, which examined how many extended relatives had been tested for FXS, was a family-level analysis and included the following variables: family income, impact of FXS on family, and how much the family talked to their relatives about FXS. The predictor variables were selected as they were thought to be highly associated with variations in the dependent variables.
Ethics Prior to contact with any human subjects, the data collection instruments and procedures were reviewed and approved by our Institutional Review Board (IRB). Informed consent was obtained online from all participants prior to the start of the survey.
Results

Family History of FXS and Testing Children
Most families (85 %) did not know that anyone in the family had a history of FXS before their first child was diagnosed. Of those who did know (n = 68), 50 % said they knew they were carriers of FXS. No differences were found between those who knew they were carriers and those who did not based on gender of the respondent or family income; however, statistically significant differences were seen for age, with younger respondents (≤40 years, 11 %) being more likely to know they were carriers than older respondents (≥51 years, 2 %), χ 2 (10, n = 651) = 25.97, p = .004. Most families (84 %) had tested all of their children for FXS, 11 % had tested at least half but not all of their children, and 5 % had fewer than half of their children tested. For those who had not tested all their children (n = 124), we asked the reason why. Most of these families (68 %) said that the child does not show signs of FXS. Another 10 % indicated that the testing was too expensive, and 6 % said they did not want to know yet. Other reasons (15 %) for not testing were that the child was adopted or preimplantation genetic diagnosis was used, or the proband child with FXS was recently diagnosed and there were plans to test the other children in the family but it had not been done yet. For each of these reasons, we examined variations in responses based on age and gender of the child, but no statistically significant differences were found. When asked if or when they will test children for FXS, 30 % of respondents indicated that they do not plan to test their child, 24 % had not decided, 21 % said when child is old enough to understand and accept the information, and 21 % had other reasons (e.g., wait until the child is older and ready to start a family).
Logistic regression results examining factors related to whether a child had been tested are shown in Table 1 . Child gender and family history of FXS were not significant predictors of testing. Children who were older (Odds ratio [OR] = 1.03) or had more total co-occurring conditions (OR =2.57) were more likely to be tested. Families with incomes of less than $50,000 (OR =0.38) or between $75,000 and $100,000 (OR =0.49) were less likely to have their child tested when compared with families who had an income of over $100,000.
Communicating about FXS with Children
Families talked with their children about FXS occasionally (47 %) or a lot (32 %); only 16 % said they do not talk about it at all. About two-thirds of children (66 %) had been told the results of testing. When asked about reasons why they had not told their child, most (76 %) said they do not think he/she would understand the results, 18 % indicated the time wasn't right yet, 11 % indicated that the child had not asked yet, and 21 % gave some other reason. When differences in reasons for not telling test results were examined by age and gender, several statistically significant patterns emerged. Respondents of adolescents and children over 18 were more likely to indicate the child would not understand the test results, χ 2 (3, n = 318) = 10.74, p = .01, those with younger children were more likely to say the time wasn't right yet, χ 2 (3, n = 318) = 26.97, p < .001, and those who had children ages 5-12 were more likely to respond that the child had not asked yet, χ 2 (4, n = 310) = 13.90, p = .008. If a child had not been told, families were asked when they planned to tell their child the results of the testing. Almost half of respondents (46 %) said they will tell the child when he/she is old enough to understand, 17 % responded they do not plan to tell the child the test result, another 17 % said they had not decided, 5 % indicated they will tell when the child asks, and 15 % had some other reasons (e.g., too severely affected to understand). Differences were found based on age, with respondents of older children (>18 years, 52 %) more likely to respond they do not plan to tell and those with younger children (<12 years, 68 %) indicating they would tell when the child was old enough to understand, χ 2 (3, n = 318) = 7.92, p = .04, as well as gender, with parents of females (67 %) indicating that they would tell their daughter when she was old enough, χ 2 (3, n = 318) = 7.92, p = .04. Table 1 also contains results from the model predicting whether a child has been told test results. Children who were older (OR =1.05) or who had tested negative for FXS (OR =1.05) were more likely to be told the results of testing. Males (OR =0.49) and those with the premutation (OR =0.43) were less likely to be told the results of FXS testing. Total number of co-occurring conditions was not a statistically significant predictor.
Communication and Testing of Relatives
Most families talked with their relatives about FXS occasionally (51 %) or a lot (31 %), 14 % said they waited until a family member asked, and only 4 % do not talk about it at all. More than a quarter of respondents (28 %) indicated that no extended family members had been tested for FXS, 55 % said one or two relatives had been tested, and 17 % responded that most or all relatives who are at-risk had been tested. When asked how many extended family members had recevied a diagnosis of either the full mutation or premutation, 28 % indicated no one had been diagnosed, 16 % reported 1 person, 12 % indicated 2 people, 11 % said 3 people, 9 % reported 4 people, and 25 % responded 5 or more people. Table 2 presents results of the model examining predictors of whether extended relatives have sought testing. Two factors were shown to be statistically significant: families with incomes of less than $50,000 (OR =0.32) or between $75,000 and $100,000 (OR =0.47), and those who communicated some or not at all about FXS with extended family (OR =0.55) were less likely to report that their relatives have sought testing.
Discussion
Our data suggest that most families find out about FXS after their first child is diagnosed. The vast majority of respondents (85 %) had no knowledge of a history of FXS in their family. This supports earlier work examining how families discover FXS (Bailey et al. 2009; Bailey et al. 2003) . However of the small number of families who knew of a family history, 50 % knew that a parent was a carrier before their first child was diagnosed. These results echo similar findings of reproductive decision making in FXS. Raspberry and Skinner (2011) conducted qualitative interviews with women who had a child already diagnosed with FXS and found a subset who chose to either continue a pregnancy or risk the 50 % chance of passing on their FXS gene in a subsequent pregnancy. These women did not frame their decision around genetic responsibility (Novas and Rose 2000) and the obligation to manage risk but rather stated their decision was grounded in a moral framework based on choice, affirmation, and love. Similar work has been conducted in Huntington's disease. Women who knew they had a genetic risk were interviewed and a decision making model emerged based on three possibilities: accepted risk, modified risk, and avoided risk (Downing 2005) . There were those who accepted the possibility of passing on their affected gene to their offspring and pursued subsequent pregnancies, those who modified their risk by having prenatal testing and then an abortion if the fetus was affected, and those who Bchose not to choose^ (Kelly 2009 ) and avoided subsequent pregnancies. Our results were in keeping with the accepted risk model given that respondents in our study who, although they had not yet had a child who had been diagnosed with FXS, chose to pursue a pregnancy despite their genetic risk. An important finding for this study was variation of carrier knowledge based on respondent age, with younger respondents being more likely to know their FXS status prior to having a child. The Raspberry and Skinner study found no differences based on knowledge of the heredity of FXS, age, education, income, ethnicity, religious affiliation, or religiosity.
For most families in our study, all of their children had been tested. When children who were at risk had not been tested, the most common reason given by parents was because the child showed no signs of FXS. Interestingly, no differences were found based on gender or age. This is concordant with the modeling results that showed the total co-occurring conditions was the strongest predictor of testing. The ACMG recommends testing for FXS if an individual either has associated symptoms (e.g., developmental delay, behavioral comorbidities) or has a family history of FXS (Sherman et al. 2005) . Moreover, the ACMG and AAP policy statement issued by the Social, Ethical, and Legal Issues Committee recommend predictive testing for children who are at risk for developing genetic conditions if parents, and ideally the children themselves, provide consent (Fallat et al. 2013; Ross et al. 2013) . Our data indicate that most parents who did not test all their children followed a symptom-based testing approach rather than a risk based approach. Hesitation on the part of parents to pursue testing of asymptomatic siblings may echo similar ethical and social concerns evoked in newborn screening which includes detection of those with the premutation of FXS. Bailey and colleagues identified several concerns in testing for and disclosing carrier status, such as the potential for increased anxiety and negative self-concept, stigmatization, and disregarding the child's right to consent later in life (Bailey et al. 2008b) . However, the identification of a child as a carrier may have positive outcomes as well, such as providing information for future reproductive planning and possible health risks (Tassone 2014) .
Fewer children had been told the test results (66 %). Factors that played a role in this were age but not severity (i.e., total co-occurring conditions). Males, younger children, and those with the premutation were less likely to be told test results. When asked when they planned to tell their children test results, many respondents indicated when they were old enough to understand the information (46 %), especially if they had a daughter or younger children. Although another 34 % said they either had not decided if they were going to share the results or had already decided not to tell their child, the latter choice was more likely for parents of males. The reluctance to share premutation results immediately or at all may, in part, be due to the perceived lower risk of developing secondary conditions or later reproductive risk (Sullivan and McConkie-Rosell 2010) . Others have speculated that clinicians may need to consider the effect of communicating results on children's emotional wellbeing as a factor in deciding whether to test children for genetic conditions (Wade et al. 2010 ). This same reason may have contributed to parent's decision to wait to tell the child until they could fully understand the information being communicated and the implications of the results. Whereas the majority of respondents (79 %) talk occasionally or a lot about FXS with their relatives, only 37 % report many or most of their relatives at risk have been tested. An additional 28 % report no relatives have been tested. Amount of communication and family income were determinants of cascade testing, but not the positive or negative impact of FXS on the family. Previous research has shown that the way in which genetic risk information is communicated to extended family members plays a role in whether relatives sought testing (McClaren et al., 2013) . Although our study did not assess which family members sought testing based on distance of the genetic relationship (e.g., first degree relatives, second degree relative), this has been shown to be associated with the number of relatives tested (Forrest et al., 2012; van Rijn et al. 1997) . Other factors that have been shown to be associated with a low uptake rate are perceived irrelevance, lack of awareness of the condition, and plans for conducting testing in the future (McClaren et al.) . Interestingly, the impact of FXS on the family did not predict the number of relatives who sought testing, indicating that a negative impact on the family did not translate to more or fewer relatives seeking testing due to worry about the ramifications of FXS on their own families.
Study Limitations
A number of limitations of the study should be noted to aid in interpreting the results. First, although our sample was the largest to date that examined family communication and cascade testing in FXS, it is not nationally representative. There were small numbers of families from minority backgrounds or with lower incomes. Another limitation to the generalizability of the findings is that many of the families in our sample were recruited through national parent advocacy organizations and as such they may be more likely to accept the diagnosis, test their children, and communicate openly with relatives. A third important caveat is that this study used survey methodology and not in-person data collection, genetic testing results were based on respondent report and were not verified clinically. Finally, there is the possibility that some of the respondents were from the same extended family and therefore our data may not be independent; for example, two sisters who both had a child with FXS could have participated in the survey and reported similar data on cascade family testing. Despite these limitations, this study provides needed large scale data on family communication and cascade testing in FXS.
Practical Implications
These findings underscore the important role of genetic counselors in ensuring that families understand the inheritance of FXS and are knowledgeable about reproductive options and associated risks both prior to having any children or once a child has been diagnosed with FXS. Risk models (i.e., accepted, modified, and avoided) should be presented and explained to families to help inform their decisions. Genetic counselors should be aware that there may be differences in reproductive choices based on age of parent or income level. Likewise, it's critical for parents to understand the risk for siblings once a child in the family has been diagnosed. Genetic counselors should acknowledge that children are still at risk for the full or premutation even if they are not currently showing signs of FXS. Parents can use this information in order to make informed choices about predictive testing.
In order to assist families with the communication of test results to their children, genetic counselors may need to have one or more meetings with families to discuss the most appropriate time to share genetic information and how to do so in a developmentally appropriate manner. Genetic counselors should encourage families to communicate openly with relatives and offer support to help inform extended family about the risk for FXS and provide information on ways to seek testing (Forrest et al. 2007 ). Examples of support could be helping to craft letters to share information with family members and assisting with identifying a Btrusted sourceŵ ithin the family. Finally, it is important for genetic counselors to keep in mind the nature of expression of the premutation, both in working with a family member who may have the premutation (e.g., potentially higher levels of anxiety) and communicating the continuum of severity to those seeking testing.
Research Recommendations
Further research is needed to better understand the reasons why families do not test all their children who are at risk for FXS. A symptom-based testing approach emerged as a possible explanation. However, reasons for not seeking testing were not related to the age or gender of the child despite both of these variables being significant predictors of who had been tested. Additional work to tease apart when and why FXS testing is sought is needed. Both qualitative and quantitative data would help to get a full understanding of testing for FXS within the immediate family.
A second area of work should examine the need for, development, and testing of decision aids to help families understand and talk about the heredity of FXS. Other studies have looked at the beast ways to share information with extended families by developing effective interventions or health communication materials (Daly et al. 2001; Wakefield et al. 2007 ). This information could be adapted for use in FXS and could build on earlier work that developed a decision aid for families who were considering newborn screening for FXS (Bailey et al. 2013 ).
